-Search query
-Search result
Showing all 43 items for (author: fukuhara & h)
EMDB-36724:
Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 1)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-36726:
Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 2)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-36727:
Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (1-up state)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-36728:
Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (2-up state)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-36729:
Structure of SARS-CoV-2 XBB.1.5 spike RBD in complex with ACE2
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-36905:
SARS-CoV-2 BA.1 RBD with UT28-RD
Method: single particle / : Chen L, Kita S, Anraku Y, Maenaka K
EMDB-36906:
SARS-CoV-2 BA.1 spike with UT28-RD
Method: single particle / : Chen L, Kita S, Anraku Y, Maenaka K
EMDB-34741:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-34742:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11 focused on RBD and NIV-11 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgl:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgm:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33820:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 focused on RBD and NIV-8 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33821:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33822:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33823:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 focused on RBD and NIV-10 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33824:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33825:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33826:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33827:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 focused on RBD and NIV-13 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33828:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33829:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33830:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh6:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-8
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh7:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-35622:
SARS-CoV-2 XBB.1 spike glycoprotein (closed-1 state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-35623:
SARS-CoV-2 XBB.1 spike glycoprotein (closed-2 state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-35624:
SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (1-up state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-35626:
SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 focused on RBD-ACE2 interface
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8ios:
Structure of the SARS-CoV-2 XBB.1 spike glycoprotein (closed-1 state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8iot:
Structure of the SARS-CoV-2 XBB.1 spike glycoprotein (closed-2 state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8iou:
Structure of SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (1-up state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8iov:
Structure of SARS-CoV-2 XBB.1 spike RBD in complex with ACE2
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-35625:
SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (2-up state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-34221:
SARS-CoV-2 BA.2.75 spike glycoprotein (closed state 1)
Method: single particle / : Anraku Y, Tabata-Sasaki K, Kita S, Fukuhara H, Maenaka K, Hashiguchi T
EMDB-34222:
SARS-CoV-2 BA.2.75 spike glycoprotein (closed state 2)
Method: single particle / : Anraku Y, Tabata-Sasaki K, Kita S, Fukuhara H, Maenaka K, Hashiguchi T
EMDB-34223:
SARS-CoV-2 BA.2.75 spike glycoprotein (1-up state)
Method: single particle / : Anraku Y, Tabata-Sasaki K, Kita S, Fukuhara H, Maenaka K, Hashiguchi T
EMDB-34224:
SARS-CoV-2 BA.2.75 spike glycoprotein in complex with ACE2
Method: single particle / : Anraku Y, Tabata-Sasaki K, Kita S, Fukuhara H, Maenaka K, Hashiguchi T
PDB-8gs6:
Structure of the SARS-CoV-2 BA.2.75 spike glycoprotein (closed state 1)
Method: single particle / : Anraku Y, Tabata-Sasaki K, Kita S, Fukuhara H, Maenaka K, Hashiguchi T
EMDB-33103:
Cryo-EM structure of human galanin receptor 2
Method: single particle / : Ishimoto N, Kita S, Park SY
PDB-7xbd:
Cryo-EM structure of human galanin receptor 2
Method: single particle / : Ishimoto N, Kita S, Park SY
EMDB-33045:
SARS-CoV-2 spike glycoprotein in complex with neutralizing antibody UT28K
Method: single particle / : Ozawa T, Tani H, Anraku Y, Kita S, Igarashi E, Saga Y, Inasaki N, Kawasuji H, Yamada H, Sasaki S, Someoka M, Sasaki J, Hayakawa Y, Yamamoto Y, Morinaga Y, Kurosawa N, Isobe M, Fukuhara H, Maenaka K, Hashiguchi T, Kishi H, Kitajima I, Saito S, Niimi H
EMDB-30566:
Human SECR in complex with an engineered Gs heterotrimer
Method: single particle / : Fukuhara S, Kobayashi K, Kusakizako T, Shihoya W, Nureki O
PDB-7d3s:
Human SECR in complex with an engineered Gs heterotrimer
Method: single particle / : Fukuhara S, Kobayashi K, Kusakizako T, Shihoya W, Nureki O